Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 4/20 | 0.40 |
| ▸ | NQO2 | P16083 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1146714 | 0.97 | MAPT (0.50) | MAPTALDH1A1HPGDGLAACHE | |
| Iodide SCHEMBL1471059 | 0.95 | MAPT (0.53) | MAPTALDH1A1HPGDGLAACHE | |
| SCHEMBL50667 | 0.92 | MAPT (0.56) | MAPTALDH1A1HPGDGLAACHE | |
| Hydrochloric Acid SCHEMBL740017 | 0.90 | MAPT (0.53) | MAPTALDH1A1HPGDGLAACHE | |
| Hydrochloric Acid SCHEMBL31542018 | 0.90 | MAPT (0.53) | MAPTALDH1A1HPGDGLAACHE | |
| Iodide SCHEMBL12813168 | 0.80 | HTR3A (0.46) | MAPTALDH1A1HPGDGLAACHE | |
| SCHEMBL3360974 | 0.79 | MAPT (0.42) | MAPTALDH1A1HPGDGLAACHE | |
| SCHEMBL8987972 | 0.78 | MAPT (0.40) | MAPTALDH1A1HPGDGLAACHE | |
| Iodide SCHEMBL2590189 | 0.78 | KDM4E (0.40) | KDM4EKCNH2 | |
| Iodide SCHEMBL12813166 | 0.78 | HTR3A (0.47) | MAPTALDH1A1HPGDGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371744-B2 | Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents | PHOTOPHARMICA LIMITED (GB) | 2008-05-13 | — | — | US | claimed |
| US-7344823-B2 | Transient optical state change materials useful in copy-protected compact discs | VERIFICATION TECHNOLOGIES, INC. (US) | 2008-03-18 | — | — | US | claimed |
| EP-4651874-A2 | PHENOTHIAZINYL COMPOUNDS AND USES | Prosetta Biosciences, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20240300940-A1 | Phenothiazinyl Compounds and Uses | PROSETTA BIOSCIENCES, INC., | 2024-09-12 | — | — | US | disclosed |
| WO-2024178120-A2 | PHENOTHIAZINYL COMPOUNDS AND USES | PROSETTA BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-9540405-B2 | Diaminophenothiazinium derivatives for labelling biomolecules, method and substrate for labelling oligonucleotides, and oligonucleotides obtained | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2017-01-10 | — | — | US | disclosed |
| US-20150011712-A1 | DIAMINOPHENOTHIAZINIUM DERIVATIVES FOR LABELLING BIOMOLECULES, METHOD AND SUBSTRATE FOR LABELLING OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2015-01-08 | — | — | US | disclosed |
| US-8809317-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120302556-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302557-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | PHOTOPHARMICA LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| WO-2006032847-A1 | WOUND HEALING | PHOTOPHARMICA LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
| EP-1551817-A2 | TRANSIENT OPTICAL STATE CHANGE MATERIALS USEFUL IN COPY-PROTECTED COMPACT DISCS | Verification Technologies, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005054217-A1 | DEVELOPMENTS IN BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES (2) | PHOTOPHARMICA LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| EP-1532623-A1 | MATERIALS FOR OPTICAL MEDIUM COPY-PROTECTION TRANSIENTLY REACTING TO A READER BEAM | Verification Technologies, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040147508-A1 | Biologically active methylene blue derivatives | PHOTOPHARMICA LIMITED | 2004-07-29 | — | — | US | disclosed |
| US-20040121262-A1 | Transient optical state change materials useful in copy-protected compact discs | SPENCER TRASK HEALTHCARE VENTURES LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004029672-A2 | TRANSIENT OPTICAL STATE CHANGE MATERIALS USEFUL IN COPY-PROTECTED COMPACT DISCS | VERIFICATION TECHNOLOGIES, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040004922-A1 | Materials for optical medium copy-protection transiently reacting to a reader beam | VERIFICATION TECHNOLOGIES, INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003107331-A1 | MATERIALS FOR OPTICAL MEDIUM COPY-PROTECTION TRANSIENTLY REACTING TO A READER BEAM | VERIFICATION TECHNOLOGIES, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011712-A1 | DIAMINOPHENOTHIAZINIUM DERIVATIVES FOR LABELLING BIOMOLECULES, METHOD AND SUBSTRATE FOR LABELLING OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED | POLRMT, RNASEH1, PDXK | ACHE 2906/4885CHRM1 678/4885MAPT 2623/4885 |
| US-20120302557-A1 | BIOLOGICALLY ACTIVE METHYLENE BLUE DERIVATIVES | NR2E3, NR1I3, NR0B2 | ACHE 4389/4885CHRM1 708/4885MAPT 3870/4885 |
| US-20040147508-A1 | Biologically active methylene blue derivatives | HCCS, CYBA, HMBS | ACHE 4014/4885CHRM1 1062/4885MAPT 1623/4885 |
| US-20120302556-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | ACHE 737/4885CHRM1 4826/4885MAPT 1569/4885 |
| US-20040121262-A1 | Transient optical state change materials useful in copy-protected compact discs | RAD51, VCL, TRRAP | ACHE 2336/4885CHRM1 3281/4885MAPT 179/4885 |
| US-20240300940-A1 | Phenothiazinyl Compounds and Uses | PSEN1, ACE, APP | ACHE 5/4885CHRM1 1580/4885MAPT 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.